iBio, Inc.

IBIO

US4510337086

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:10:00 2024-05-13 pm EDT			5-day change	1st Jan Change
1.815 ^USD	-1.87%		-8.77%	+32.51%

Apr. 01	IBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors	CI
Mar. 28	Top Premarket Gainers	MT

Ibio, Inc. Reports Earnings Results for the Full Year Ended June 30, 2021

September 27, 2021 at 07:30 am EDT

iBio, Inc. announced earnings results for the full year ended June 30, 2021. For the full year, the company announced sales was USD 2.371 million compared to USD 1.638 million a year ago. Operating loss was USD 31.111 million compared to USD 14.003 million a year ago. Net loss was USD 23.207 million compared to USD 16.439 million a year ago. Basic loss per share from continuing operations was USD 120.000000 compared to USD 610.000000 a year ago. Diluted loss per share from continuing operations was USD 0.12 compared to USD 0.61 a year ago.

Latest news about iBio, Inc.

IBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors	Mar. 31	CI
Top Premarket Gainers	Mar. 28	MT
Top Midday Gainers	Mar. 27	MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	Mar. 27	MT
Transcript : IBio, Inc. - Special Call	Mar. 27
US Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data Readings	Mar. 27	MT
Top Premarket Gainers	Mar. 27	MT
IBio, Inc. and AstralBio, Inc. Announce Transformative AI Drug Discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases	Mar. 27	CI
IBio, Inc. announced that it has received $14 million in funding	Mar. 25	CI
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka	Feb. 26	DJ
Otsuka Pharmaceutical Co., Ltd. completed the acquisition of Preclinical PD-1 Agonist Antibody Program of iBio, Inc..	Feb. 24	CI
IBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 09	CI
Top Midday Decliners	Dec. 05	MT
Top Premarket Decliners	Dec. 05	MT
North American Morning Briefing : November Rally Pauses Ahead of This Week's PCE Report	Nov. 28	DJ
IBio Board Approves 20-to-1 Reverse Split of Common Stock Effective Nov. 29; Shares Sink 11% After Hours	Nov. 27	MT
IBio, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
IBio, Inc. Announces Expansion of its AI-Powered Technology Stack with Launch of ShieldTx	Nov. 01	CI
North American Morning Briefing : Stock Futures, -2-	23-10-02	DJ
IBio, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-27	CI
North American Morning Briefing : Stock Futures -2-	23-09-25	DJ
IBio Unit, Woodforest National Bank Amend Credit Agreement	23-09-21	MT
IBio, Inc. Reports Triple Milestone in Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development	23-08-14	CI
IBio, Inc. announced that it expects to receive $10 million in funding from Lincoln Park Capital, LLC	23-08-03	CI
IBio Names Martin Brenner Chief Executive; Felipe Duran Appointed as Finance Chief	23-06-27	MT

Chart iBio, Inc.

Duration

Period

More charts

Company Profile

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, and CCR8. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

Sector

Pharmaceuticals

Calendar

2024-09-23 - Q4 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
IBIO, INC.	+32.51%	15.63M
ELI LILLY AND COMPANY	+29.98%	682B
NOVO NORDISK A/S	+30.34%	586B
JOHNSON & JOHNSON	-3.52%	364B
MERCK & CO., INC.	+18.59%	327B
ABBVIE INC.	+4.07%	285B
ASTRAZENECA PLC	+16.21%	240B
NOVARTIS AG	+9.66%	209B
ROCHE HOLDING AG	-6.83%	203B
AMGEN INC.	+7.09%	165B

Other Pharmaceuticals

iBio, Inc.

Equities

IBIO

US4510337086

Pharmaceuticals

Ibio, Inc. Reports Earnings Results for the Full Year Ended June 30, 2021

Latest news about iBio, Inc.

Chart iBio, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals